HYAL2 and neoplasm: In particular, the hyaluronan-enriched intratumoral ECM promotes the transition of tumor-recruited hyaluronidase 2-expressing myeloid-derived suppressor cells (MDSCs) of bone marrow origin to the tumor-associated PD-L1+ macrophages that actively remodel the TME toward its immunosuppressive and proinflammatory variant [70].